Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors
The Pharma Data
JANUARY 18, 2021
Invir.IO ’s viruses are based on the patented large capacity Vaccinia virus Copenhagen strain genetically modified with the double deletion TK – RR – This optimization enhances the safety profile of the virus. The recombinant antibody recognizing human CTLA4 was generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T
40 
Let's personalize your content